ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

Cabozantinib

HCID 178955845
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1802168-46-2
標準SMILES
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
InChIKey
ONIQOQHATWINJY-UHFFFAOYSA-N
分子式
C28H24FN3O5
平均分子量
501.5 g/mol

概要

Cabozantinib is a dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a member of quinolines, an aromatic ether, a dicarboxylic acid diamide and an organofluorine compound.

名称と識別子

優先名称
Cabozantinib
IUPAC
1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
英語名
Cabozantinib-d6
分子式
C28H24FN3O5
分子量
501.51

名称と別名

Cabozantinib849217-68-1XL-184XL 184BMS-907351XL-184 free baseBMS 907351N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideCHEBI:723171C39JW444GBMS-907351 FREE BASEXL184 cpd
名称をさらに表示
Cabozantinib-d6Cabozantinib bis(Trideuteromethoxy)Cabozantinib-d6Q: What is Cabozantinib-d6 Q: What is the CAS Number of Cabozantinib-d6
BMS907351DTXSID102339681,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamidecabozantinibum1,1-CYCLOPROPANEDICARBOXAMIDE, N'-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N-(4-FLUOROPHENYL)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideRefChem:57604

データベース識別子

CAS
1802168-46-2
ChEMBL
CHEMBL2105717
ChEBI
CHEBI:72317

物性

構造計算による物性補完中

XLogP
5.4
極性表面積
98.8 Ų
水素結合供与体数
2
水素結合受容体数
7
回転可能結合数
8
重原子数
37
形式電荷
0
複雑度
795

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antineoplastic and immunomodulating agents -> Antineoplastic agents

SolubilityCOMETRIQ is practically insoluble in water.
Human Drugs · 4 件

Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors;

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine (Orphan designations)

物理化学的性質

貯蔵温度
4 °C, · 4°C, protect from light
溶解性
120 mg/mL · DMSO : 120 mg/mL (236.43 mM; Need ultrasonic)
外見
Solid
色
White to off-white

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

Hepatotoxicity · 1 件

In large clinical trials of cabozantinib, elevations in serum aminotransferase levels were common, occurring in 16% to 97% of patients. Values greater than 5 times the upper limit of normal (ULN), however, occurred in only 2% to 8% of recipients. Serum alkaline phosphatase elevations were also common and were above 3 times ULN in 3% of patients. Despite the high rate of serum enzyme elevations, cases of clinically apparent liver injury including acute liver failure were not reported in the preregistration trials of cabozantinib. Since the approval of cabozantinib, there have been no published case reports of hepatotoxicity attributed to its use. Serum ALT, AST and alkaline phosphatase elevations are listed as adverse reactions in the product label for cabozantinib, and cholestatic hepatitis is mentioned as a rare occurrence, but monitoring of serum enzymes during treatment is not specifically recommended.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

化学と産業

薬理情報

ATC Code · 3 件

L01XE26

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingCabozantinib has extensive plasma protein binding (≥ 99.7%).
PharmacodynamicsCabozantinib suppresses metastasis, angiogenesis, and oncognesis by inhibiting receptor tyrosine kinases.
Mechanism of ActionCabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.
Biological Half-LifeCabozantinib has a long half-life of 55 hours.
Metabolism/MetabolitesCabozantinib is metabolized mostly by CYP3A4 and, to a minor extent, by CYP2C9. Both enzyme produce an N-oxide metabolite.
FDA Pharmacological Classification · 6 件

1C39JW444G

CABOZANTINIB

Established Pharmacologic Class [EPC] - Kinase Inhibitor

Mechanisms of Action [MoA] - Protein Kinase Inhibitors

Cabozantinib is a Kinase Inhibitor. The mechanism of action of cabozantinib is as a Protein Kinase Inhibitor.

CABOZANTINIB

Absorption, Distribution and Excretion · 4 件

After oral administration, peak plasma concentration was achieved in 2-5 hours.

Cabozantinib is eliminated mostly by the feces (54%) and also by the urine (27%).

The volume of distribution is 349L.

At steady state, the clearance is 4.4 L/hr.

応用分野 · 1 件

Cabozantinib-d6 is the labelled analogue of Cabozantinib (X745500), a medication used to treat medullary thyroid cancer. As well it can be used in biological study. Computational network biological approach based on pathway cross-talk inhibition identified new synergistic drug combinations using raloxifene and cabozantinib for treatment of human breast cancer in xenograft mouse model. Potent c-MET inhibitor.

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
UNII
1C39JW444G
Nikkaji
J3.085.595G
使用